Profile of panobinostat and its potential for treatment in solid tumors: an update

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Histone deacetylase (HDAC) inhibitors are emerging as novel cancer therapies.
• Panobinostat (LBH 589) is a pan-deacetylase inhibitor evaluated in various formulations and tumor types.

Purpose of the Study:

• To review the current status of panobinostat.
• To discuss the role of panobinostat in treating solid tumors.

Main Methods:

• Review of preclinical data on panobinostat's efficacy.
• Analysis of panobinostat's mechanism of action, including histone hyperacetylation and apoptosis induction.
• Evaluation of clinical trial data for panobinostat in solid tumors.

Main Results:

• Panobinostat induces hyperacetylation of histones and other proteins, leading to repressed gene expression, inhibited cellular proliferation, and apoptosis.
• Panobinostat activates cellular death receptor pathways, contributing to apoptosis.
• Preclinical data indicate potent inhibitory activity at nanomolar concentrations, positioning it as a highly potent HDAC inhibitor.

Conclusions:

• Panobinostat demonstrates significant preclinical potency and a dual mechanism for inducing cancer cell death.
• Further investigation into panobinostat's role in solid tumor treatment is warranted.